| アブストラクト | BACKGROUND: Sodium zirconium cyclosilicate (SZC) is a novel oral therapy for hyperkalemia with limited adverse reactions documented on its label. Accordingly, the objective of this study was to investigate real-world adverse events (AEs) associated with SZC using the FDA Adverse Event Reporting System (FAERS). RESEARCH DESIGN AND METHODS: Relevant data regarding SZC were extracted from FAERS, and signal detection was conducted using four distinct algorithms. The Weibull shape parameter characterized the AE onset time. Kaplan-Meier analysis was used to evaluate the cumulative incidence of AEs associated with SZC. RESULTS: Among 8,846,085 case reports recorded in the FAERS database, 1,160 SZC-related AEs were identified. Beyond AEs, such as hypokalemia, edema, constipation, and ileus, listed on the SZC label, 26 additional positive risk signals were not stated, including X-ray gastrointestinal tract abnormal, cardiac failure, and aspiration pneumonia. The median onset time of SZC-related AEs was 42 days. Furthermore, AEs differed between male and female patients. CONCLUSIONS: This study confirmed SZC label safety warnings and identified new AEs, offering insights for clinical monitoring of SZC. |
|---|
| 組織名 | Department of Oncology, Yongchuan Hospital of Chongqing Medical University,;Chongqing, China.;Department of Pharmacy, Qijiang Health Center for Maternal and Child Care,;Department of Pharmacy, Yongchuan Hospital of Chongqing Medical University, |
|---|
